Posted by Michael Wonder on 31 Oct 2018
Schedule of Pharmaceutical Benefits - 1 November 2018 update
1 November 2018 - The November 2018 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.
The November issue of the Schedule includes a number of new/revised listings:
- Apomorphine hydrochloride monohydrate (Movapo PFS) - new formulation
- Dexamethasone (Ozurdex) - new indication
- Evolocumab (Repatha) - new indication
- Obinutuzumab (Gazyva) - restriction change
- Pembrolizumab (Keytruda) - new indication
- Ranibizumab (Lucentis) - new indication
